Breaking new ground in Blood Cancer research – The Leukemia and Lymphoma Society
The Leukemia and Lymphoma Society shared a post on LinkedIn:
“We’re breaking new ground in Blood Cancer research.
Lore Gruenbaum has stepped into her role as Chief Scientific Officer with a bold mission: to fund cutting-edge research that impacts patients today while planting seeds for the treatments of tomorrow.
‘It’s a privilege to lead a group of dedicated LLS scientists to seek out and fund innovative science for every type of blood cancer,’ says Dr. Gruenbaum.
From groundbreaking therapies for acute myeloid leukemia (AML) to the transformative power of AI and advancements in early intervention, 2025 is shaping up to be a year of progress. Discover what’s on the horizon.”
Lore Gruenbaum is the Chief Scientific Officer at The Leukemia and Lymphoma Society, where she previously led the Therapy Acceleration Program. With extensive experience in biomarker strategy, translational research, and drug development, she has held senior roles at Gotham Therapeutics, Applied BioMath, Roche, and Boehringer Ingelheim. Dr. Lore holds a Ph.D. in Biochemistry from Freie Universität Berlin and completed postdoctoral research in Neuroscience at Yale University.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023